Nachrichten zur Intellia Therapeutics Inc. Aktie

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

…

Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript

…

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Theres nothing bearish at all about what it reported recently.…

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? @themotleyfool #stocks $NTLA

Theres nothing bearish at all about what it reported recently.…

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

…

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study By Investing.com

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study…

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street @themotleyfool #stocks $NTLA

Intellia Therapeutics innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.…

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics Announces CFO Transition

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics: "buy"

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist stufen die Aktie von Intellia Therapeutics Inc. (ISIN: US45826J1051, WKN: A2AG6H, Ticker-Symbol:…

Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

…

Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com

Earnings call: Intellia Therapeutics reports robust Q1 progress…

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Is Intellia Therapeutics Stock a Buy Now?

The companys future will depend on its innovative qualities.…

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

2024 could see the start of its first late-stage clinical trials.…

Intellia Therapeutics, Inc. (NTLA) Q4 2023 Earnings Call Transcript

…

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

Both companies are going to continue doing high-impact science in 2024.…

Biotech Market Forecast: Top Trends That Will Affect Biotech in 2024

The biotech sector is a dynamic and constantly evolving industry that is driving scientific advancements and innovation in healthcare. According…

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

These two are at very different stages of the clinical trials process.…

Intellia Therapeutics files for mixed shelf

…

Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester

Leading genome editing market players include Merck KGaA, Horizon Discovery Ltd., Lonza Group Ltd., Twist Bioscience Corporation, Akron Biotech., CRISPR…

Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript

…

Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics,…

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

Intellias (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline....…

Form 8-K Intellia Therapeutics, For: Aug 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Insiderhandel: Aufsichtsrat verkauft Aktien von Intellia Therapeutics im Wert von 73.373$

Bhanji, Muna - Aufsichtsrat - Tag der Transaktion: 2023-07-06...…

Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?

Pre-revenue biotechs dont have many ways to juice their share prices....…

Insiderhandel: EVP, Chief Technical Officer verkauft Aktien von Intellia Therapeutics im Wert von 225.000$

Clark, Eliana - Vorstand - Tag der Transaktion: 2023-06-20...…

Form 8-K Intellia Therapeutics, For: Jun 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Intellia (NTLA) Up on Positive Data Updates From HAE Study

Intellias (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema....…

Intellia Therapeutics stock gains on CRISPR treatment results

Intellia Therapeutics Inc. NTLA shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from…

Intellia Therapeutics Shares Rise After Reporting Data For CRISPR Treatment

Intellia Therapeutics Shares Rise After Reporting Data For CRISPR Treatment...…

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., June 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

dpa-AFX ProFeed